Pancreatic Cancer Screening for Pancreatic Cancer
(CAPS5 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is overseen by Johns Hopkins clinical research office. Team members at each location will report any major issues to the lead researcher.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
Is the CA19-9 test safe for humans?
How does this treatment for pancreatic cancer differ from other treatments?
This treatment is unique because it focuses on using glycan-based biomarkers, specifically sialyl-Lewis A (sLeA) and sialyl-Lewis X (sLeX), to improve the detection and classification of pancreatic cancers. Unlike the standard CA19-9 biomarker, which is not elevated in about 25% of pancreatic cancer cases, this approach can identify additional cancer cases by detecting related glycans, potentially leading to more accurate diagnosis.12678
What data supports the effectiveness of the treatment CA19-9 for pancreatic cancer screening?
CA19-9 is the most commonly used biomarker for diagnosing pancreatic cancer in symptomatic patients and monitoring therapy, although it has limitations such as false negatives and positives. It is currently the best validated serum tumor marker for pancreatic cancer, despite not being a perfect screening tool.12359
Who Is on the Research Team?
Michael Goggins, MD
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for individuals with a scheduled endoscopic evaluation of the pancreas, who either have Hereditary Pancreatitis, Peutz-Jeghers Syndrome, a strong family history of pancreatic cancer, or specific genetic mutations. It's not suitable for those with upper GI tract obstructions, inability to consent, conditions that make endoscopy risky, certain prior surgeries like gastrectomy or if pregnant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pancreatic Surveillance
Participants undergo pancreatic screening and surveillance, including evaluation of pancreatic fluid mutations and circulating pancreatic epithelial cells.
Follow-up
Participants are monitored for safety and effectiveness after initial screening and surveillance activities.
What Are the Treatments Tested in This Trial?
Interventions
- CA19-9
- Human Synthetic Secretin
- MRI
- Secretin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
American Association for Cancer Research
Collaborator
ChiRhoClin, Inc.
Industry Sponsor
National Institutes of Health (NIH)
Collaborator